IP Library Granted Patent US 7,781,398
Granted Patent B2
US 7,781,398 · App. 11/643,342 · Granted Aug 24, 2010

Drug comprising synthetic peptide analogs for the treatment of cancer

Assignee: Dabur Pharma Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,781,398
App. No.
11/643,342
Granted
Aug 24, 2010
Kind
B2
Abstract

The present invention relates to a combination of peptides that may be used for treatment of cancer. The peptide combination competes for the binding of specific neuropeptides at the plasma membrane and thereby alters the levels of key intracellular molecules implicated in cell proliferation, resulting in a broad spectrum of anticancer activity. The invention also relates to pharmaceutical compositions containing a combination of such peptide analogs.

Claims (7)

1. A method of killing or inhibiting the multiplication of tumor cells or cancer cells in a human or other animal, the method comprising administering to the human or animal an amount of a combination comprising peptides SEQ ID:1, SEQ ID:2, SEQ ID:3 and SEQ ID:4 or pharmaceutically acceptable salt(s) thereof effective to kill or inhibit the multiplication of tumor cells or cancer cells.

2. The method according to claim 1 , wherein the concentration of each peptide in the combination is about 10 −6 M to 10 −10 M.

3. The method according to claim 1 , wherein the concentration of each peptide in the combination is about 10 −8 M.

4. A method for treating leukemia, glioblastoma, colon, lung, breast, prostate, cervical, ovary, stomach, duodenum, pancreatic or oral cancer comprising administering to a human or animal in need thereof an effective amount of a combination comprising peptides SEQ ID: 1, SEQ ID: 2, SEQ ID: 3 and SEQ ID: 4 or pharmaceutically acceptable salt(s) thereof.

5. The method according to claim 4 , wherein a dose is 0.05 to 500 microgram/Kg of body weight of the human or animal.

6. The method according to claim 4 , wherein the concentration of each peptide in the combination is about 10 −6 M to 10 −10 M.

7. The method according to claim 4 , wherein the concentration of each peptide in the combination is about 10 −8 M.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2008
From: DABUR RESEARCH FOUNDATION
To: DABUR PHARMA LTD.
Reel/Frame 021301/0618 →
Continuity (2)
Division 1032932100 · Dec 23, 2002
Related Publication 20070093422A1 · Apr 26, 2007